AKT1 and lymphoma: Emerging evidence has highlighted aberrant PELI1 expression across a spectrum of malignant neoplasms (e.g., lung cancer, breast cancer, and lymphoma), where it regulates tumor cell survival, invasion, and metastasis by modulating key signaling pathways such as PI3K-AKT, NF-κB and B-cell signaling pathways (6).